Transfer of daclatasvir and sofosbuvir ’s main metabolite, GS-331007, across the human placenta ex vivo

The treatment of hepatitis C virus (HCV) infection during pregnancy is mainly focused on maternal cure, with the secondary aim of also preventing vertical transmission to the fetus. Direct-acting antivirals (DAAs) are commonly being prescribed to nonpregnant patients, but a lack of data on the pharmacokinetics, safety, and efficacy of DAAs hampers their use in pregnant patients.1 It has been hypothesized that ribavirin-free maternal treatment regimens with DAAs could be appropriate if it can be shown that treatment during pregnancy does not cause reproductive toxic adverse effect.
Source: American Journal of Obstetrics and Gynecology - Category: OBGYN Authors: Tags: Research Letter Source Type: research